EBR Systems, Inc.

EBR Systems, Inc. is a medical device company specializing in advanced treatments for cardiac rhythm disorders. Established in 2003 and headquartered in Silicon Valley, the company is dedicated to developing technologies that address the limitations of conventional cardiac resynchronization therapy (CRT). Its flagship innovation, the WiSE (Wireless Stimulation Endocardially) system, delivers leadless cardiac pacing, eliminating the traditional leads that are a frequent source of complications and reliability issues in cardiac rhythm management. By providing a physiologically effective and versatile approach to heart stimulation, EBR Systems contributes to a significant shift in the standard of care for patients with heart failure and other cardiac rhythm diseases. The company's technologies have progressed through major clinical and regulatory milestones, including first-in-human implantations, securing FDA Breakthrough Device Designation, and receiving FDA approval in 2025. EBR Systems plays a critical role in the healthcare sector, focusing on serving hospitals and cardiac specialists with life-improving solutions that enhance patient outcomes and advance the field of cardiac electrophysiology.